Handson Global Management Q1 FY26 loss at ₹2.06 cr

Key takeaway from the June-quarter results

Handson Global Management (HGM) Ltd reported a sharp deterioration in its Q1 FY26 performance, with consolidated earnings swinging from profit to loss. For the quarter ended June 30, 2026, the company posted a consolidated net loss of ₹2.0627 crore, compared with a net profit of ₹1.7270 crore in Q1 FY25. Consolidated revenue declined year-on-year, indicating a weaker topline alongside the earnings reversal. The company also disclosed that its Board of Directors took up several corporate matters on August 14, 2026, alongside approving the financial results.

Consolidated performance: revenue down, loss reported

On a consolidated basis, revenue for Q1 FY26 stood at ₹10.7989 crore, down from ₹13.6090 crore in Q1 FY25, a decline of 20.6% as reported. The consolidated net result shifted to a loss of ₹2.0627 crore in Q1 FY26 from a profit of ₹1.7270 crore a year earlier. This profit-to-loss swing is the central change in the quarter’s reported numbers. The company’s update framed the quarter as a significant deterioration compared with the corresponding period of FY25.

Standalone numbers also turn negative

HGM’s standalone financials also moved from profit to loss in the same period. Standalone revenue in Q1 FY26 came in at ₹9.7950 crore versus ₹13.6090 crore in Q1 FY25, a decline of 28.0% as reported in the results snapshot. The standalone entity recorded a net loss of ₹0.3079 crore, compared with a net profit of ₹1.7286 crore in the year-ago quarter. The standalone comparison indicates the earnings pressure was not limited to consolidated operations.

Board meeting decisions: $1 million infusion planned

During its meeting on August 14, 2026, the Board of Directors approved an infusion of up to US$ 2 million into the company’s overseas subsidiary, Healthcare Capital Holdings LLC (HCI-LLC). The subsidiary is based in the Cayman Islands, as stated in the corporate update. The disclosure did not provide a timeline for the infusion beyond the board approval, but the amount and the recipient entity were specified.

Auditor review: unmodified conclusion

The statutory auditors, Lodha & Co LLP, issued a review report with an unmodified conclusion on the unaudited consolidated and standalone financial results. This indicates that, based on the limited review, the auditors did not modify their conclusion on the quarterly numbers that were presented.

AGM date fixed for September 18, 2026

HGM announced that its 38th Annual General Meeting (AGM) is scheduled for September 18, 2026. The company said the Board of Directors approved the convening of the meeting through a circular resolution passed on July 28, 2026. These dates set a clear near-term corporate calendar item for shareholders.

Stock movement on results day

The stock was reported at ₹46.44, down ₹0.95 (2.00%) as of 11:24 AM on August 14, 2026. In the same session, HGM opened at ₹47.53 versus a previous close of ₹47.39. The day’s high was ₹47.53 and the low was ₹46.44, with an average traded price of ₹46.91. The data excerpt also cited other recent reference points, including ₹48.11 on August 12, 2026, and ₹52 as of June 28, 2026.

Results snapshot table (all ₹ in crore)

All revenue and profit or loss figures below are converted from the company’s reported ₹ lakh figures into ₹ crore for consistency.

Corporate actions and results calendar (as listed)

The company’s information feed also included a results calendar with multiple quarterly result dates.

Why this quarter matters for investors

The June-quarter update is notable because both consolidated and standalone results moved from profit to loss year-on-year, alongside reported revenue declines. Separately, the board’s approval for an overseas subsidiary infusion of up to US$ 2 million adds a capital allocation point that investors may track through subsequent disclosures. The scheduled AGM on September 18, 2026 is the next formal forum where shareholders can expect additional statutory updates and resolutions. Any further detail on the capital infusion and operational performance will depend on future filings and management communication, beyond what was disclosed in this update.